Visual Impairment News and Research RSS Feed - Visual Impairment News and Research

The definition of vision impairment by the Centers for Disease Control and Prevention (CDC) says a visually impaired person’s eyesight cannot be corrected to a “normal level”.
Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders. [More]
French Ministry of Health approves financial support for Second Sight Argus II Retinal Prosthesis System

French Ministry of Health approves financial support for Second Sight Argus II Retinal Prosthesis System

Second Sight Medical Products Inc. today announces that the French Ministry of Health has officially approved financial support for the Argus II Retinal Prosthesis System. Through the Forfait Innovation scheme, the French Government will pay for the first wave of groundbreaking treatment for 36 patients with severe to total sight loss due to retinitis pigmentosa (RP) in France. [More]
Research: New ways to help visually impaired better navigate everyday life

Research: New ways to help visually impaired better navigate everyday life

Visual impairment comes in many forms, and it's on the rise in America. A University of Cincinnati experiment aimed at this diverse and growing population could spark development of advanced tools to help all the aging baby boomers, injured veterans, diabetics and white-cane-wielding pedestrians navigate the blurred edges of everyday life. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]

Hearing problems reduce active participation of older people in various events

Vision and hearing problems reduce the active participation of older people in various events and activities. This was observed in two studies carried out by the Gerontology Research Center. [More]
Early stage AMD can occur much earlier than previously thought

Early stage AMD can occur much earlier than previously thought

It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries. [More]
Study shows correlation between education and nearsightedness

Study shows correlation between education and nearsightedness

Education and behavior have a greater impact on the development of nearsightedness than do genetic factors: With each school year completed, a person becomes more nearsighted. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
LA BioMed researchers launch new project to improve diabetes management

LA BioMed researchers launch new project to improve diabetes management

Managing diabetes is a year-round challenge for anyone living with the disease. The challenge is even greater for underserved and uninsured people who often don't have easy access to the care they need to manage their diabetes. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
Integrated therapies can reduce depression by half among people with low vision due to AMD

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD). [More]
Study links nearsightedness to higher education and years spent in school

Study links nearsightedness to higher education and years spent in school

German researchers have found strong evidence that attaining a higher level of education and spending more years in school are two factors associated with a greater prevalence and severity of nearsightedness, or myopia. [More]
New approaches needed to improve visual accessibility for people with low vision-challenges

New approaches needed to improve visual accessibility for people with low vision-challenges

New approaches and tools are needed to improve visual accessibility for people with low vision in the "real world," according to a special article in the July issue of , official journal of the the American Academy of Optometry. [More]
Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Nicox S.A., the international ophthalmic company, and Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.). [More]
Simulator for evaluating effects of visual impairment on person's driving performance

Simulator for evaluating effects of visual impairment on person's driving performance

The University of California, San Diego School of Medicine is the first ophthalmology department in the nation to feature a fully dedicated high-fidelity, highly realistic driving simulator for evaluating the effects of visual impairment on a person's driving performance. [More]
Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO). [More]
Study shows high BP drugs may raise likelihood of age-related macular degeneration

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology. [More]
Researchers working in Palestine and Jordan to help better provision of eye care

Researchers working in Palestine and Jordan to help better provision of eye care

An Aston University academic is working in Palestine and Jordan to help better the provision of eye care in the two countries as part of a €565,000 worldwide two-year project. [More]
People suffering from vision loss are twice as likely to suffer from depression

People suffering from vision loss are twice as likely to suffer from depression

People suffering from vision loss are twice as likely to suffer from depression as the general population. And many psychiatric medications can cause vision problems over time. [More]

Ranibizumab trial gets promising results for CNV

Patients with visual impairment due to myopic choroidal neovascularisation achieve better visual acuity after 3 months of individualised treatment with ranibizumab than with verteporfin photodynamic therapy, show the results of a phase III randomised controlled trial. [More]